FDA approval of the postpartum depression treatment brexanolone represents the final phase of a bench-to-bedside journey for this drug — a journey that began in the NIMH Intramural Research Program. NIMH experts are available to provide information on postpartum depression and the importance of, and the science underlying, this new drug.
from NIMH News Feed https://ift.tt/2ujtPBg
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment